Immunovant price target raised to $61 from $58 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab Myasthtenia ...
STAT2h
Alnylam enters the ATTR-CM drug race
Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.
HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT)
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...
STAT21h
Zealand’s obesity strategy and Immunovant’s curious development plan
For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal with Roche, go here; and to read about the panels at our Breakthrough East ...
Investor's Business Daily on MSN22h
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.
Shares of ARS Pharmaceuticals bounded off their 50-day line Thursday after the biotech company reported an unexpected ...